Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK needs to open its mind to brain stimulation:

This article was originally published in Clinica

Executive Summary

Some 120,000 people in the UK suffer from Parkinson's disease and about 25,000 would benefit from the £25,000 ($39,000) operation to have implanted Medtronics' deep brain stimulation device to suppress its symptoms. Yet the UK has one of the lowest uptakes in Europe, Michael Holman, Parkinson' patient and journalist at the UK's Financial Times told a meeting in Budapest, Hungary on October 10. Speaking at the annual general meeting communications forum of the European medical device industry association, Mr Holman explained that the operation is cost-effective, since it replaces many of the medication costs - which can total £3,000 a year per patient. In addition, it provides an immeasurable improvement in the quality of life of a patient. Mr Holman's talk served to illustrate the point that the industry is making that government's are turning down innovative medical technology because of its high initial costs, without considering fully the long-term benefits for all concerned.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts